U.S. FDA News

On March 22, the U.S. FDA approved pembrolizumab (Keytruda) in combination with chemotherapy for a subset of patients with advanced esophageal or gastroesophageal carcinoma. On March 27, the U.S. FDA approved idecabtagene vicleucel (Abecma), a BCMA-targeted CAR T cell therapy, for a subset of patients with multiple myeloma. This is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma.
 

LEARN MORE